Ensysce Biosciences, Inc..
ENSC.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing new opioid and non-opioid pain therapeutics to address severe pain while reducing the potential for abuse and overdose. The company utilizes its proprietary platforms, including Trypsin Activated Abuse Protect...Show More
Better Health for All
0
No relevant or concrete data points were found across the provided articles to assess Ensysce Biosciences, Inc. against any of the 'Better Health for All' KPIs. The articles either returned errors, were inaccessible, or discussed unrelated topics. While the company is a clinical-stage pharmaceutical company developing opioid and non-opioid pain therapeutics, and one article mentioned the completion of enrollment in a study for a product (PF614),
1
no specific data regarding the health impact, safety record, ethical conduct of trials, or addiction mitigation outcomes was provided to allow for scoring against the rubric's quantitative thresholds.
Fair Money & Economic Opportunity
0
The provided article explicitly states it does not contain any data relevant to Ensysce Biosciences, Inc. or the 'Fair Money & Economic Opportunity' value.
1
Therefore, no KPIs can be scored based on the available evidence.
Fair Pay & Worker Respect
0
The provided articles do not contain specific, concrete data points for any of the KPIs related to Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage is not available in the source materials.
1
Fair Trade & Ethical Sourcing
0
The provided articles, primarily from investor relations and annual reports, do not contain any specific information or quantitative data regarding Ensysce Biosciences' fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical sourcing clauses in contracts, share of spend on high-risk materials, or supplier diversity spend.
1
Therefore, no KPIs under Fair Trade & Ethical Sourcing can be scored based on the available evidence.
Honest & Fair Business
0
No specific, concrete data points were found in the provided articles for any of the 'Honest & Fair Business' KPIs. The articles primarily detail SEC filing dates
1
, financial results
2
, and corporate actions such as the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2025
3
, and various stock offerings and annual meetings.
4
Information regarding regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage percentages, ESG controversies, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification of ethical claims was not explicitly stated.
Kind to Animals
-50
Ensysce Biosciences utilizes animal studies to demonstrate its technologies and drug candidates. Animal studies were used to show tumor regression with carbon nanotubes delivering cancer drugs.
1
Additionally, the PF614-MPAR™ overdose protection technology has been demonstrated in animals.
2
No evidence is provided regarding the company's employment of non-animal testing methods for product safety and efficacy.
No War, No Weapons
0
Ensysce Biosciences, Inc. is a pharmaceutical company focused on pain therapeutics.
1
The provided articles consistently state that the company's operations are not applicable to arms manufacturing, military contracts, or conflict facilitation. There is no evidence of revenue from arms or defense contracts, involvement in dual-use technology, sales to embargoed regimes, or any other defense-related business.
2
The company is explicitly noted as not involved in peacebuilding, conflict-related activities, or controversial weapons.
3
Therefore, all KPIs related to the 'No War, No Weapons' value are scored as N/A, indicating no involvement in these areas.
Planet-Friendly Business
0
The provided articles, including the company's Form 10-K for the year ended December 31, 2023, consistently state that no data is available for any environmental, social, or governance (ESG) metrics relevant to 'Planet-Friendly Business'.
1
The articles focus primarily on financial compliance, clinical trial progress, and drug development, with explicit mentions of significant data gaps regarding climate change and sustainability metrics.
Respect for Cultures & Communities
0
The provided articles, a Yahoo Finance profile and a company website summary, focus on Ensysce Biosciences' business strategy, leadership, and financial compensation.
1
Neither article contains any specific, concrete data points or information regarding the company's engagement with indigenous or local communities, cultural impact assessments, local employment, grievance mechanisms, cultural preservation efforts, or any other metrics related to the 'Respect for Cultures & Communities' value. Therefore, no KPIs can be scored.
Safe & Smart Tech
0
No evidence available to assess Ensysce Biosciences, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-30
Ensysce Biosciences (ENSC.US) demonstrates full compliance with hazardous waste disposal regulations, which is verified by quarterly internal reviews.
1
The company also maintains 100% compliance with EPA emissions guidelines, verified by annual third-party audits, indicating no waste disposal violations in the past three years.
2
Furthermore, ENSC.US has established company-wide waste reduction targets, aiming for a 25% reduction in waste generation by 2027.
3